Dzerassa Gurtsieva,Ekaterina Minskaia,Sofia Zhuravleva,Elena Subcheva,Elena Sakhibgaraeva,Andrew Brovin,Artem Tumaev,Alexander Karabelsky
Abstract:The level of transduction efficiency of the target retinal cells affects the choice of AAV serotype and the outcome of gene replacement therapy for inherited retinal diseases. This study focused on the tropism and transduction efficiency of AAV2.7m8-, AAV5-, AAV8-, and AAV9-GFP in ARPE-19 and HEK293 cells. Fluorescence intensity was assessed bi-hourly by means of IncuCyte S3 live imaging microscopy. Within 12 h, AAV2.7m8 demonstrated the highest transduction efficiency at four viral concentrations of 1-, 3-, 6-, and 8 × 104 VG/cell in a dose-dependent manner, followed by AAV5 in ARPE-19 and AAV9 in HEK293 cells. The transduction efficiency of AAV2.7m8 at a dose of 6 × 104 VG/cell was 21, 202, and 323 times higher in ARPE-19 cells and 324, 100, and 52 times higher in HEK293 cells compared to AAV5, AAV8, and AAV9, respectively. This trend remained for 4 days at all viral concentrations, as additionally shown by flow cytometry. At a dose of 6 × 104 VG/cell, AAV2.7m8 (97% GFP-positive cells, GFP +) was nearly two and 10 times as efficient as AAV5 (52% GFP+) and AAV9 or AAV8 (both 9%), respectively, in ARPE-19 cells. In HEK293 cells, 95% of AAV2.7m8-, 26% of AAV9-, 17% of AAV8-, and 12% of AAV5-transduced cells were GFP-positive.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to determine the differences in the efficiency of different AAV serotypes in transducing human retinal cells, in order to select the AAV serotype most suitable for treating inherited retinal diseases (IRDs). Specifically, the researchers compared the transduction efficiencies of four serotypes, AAV2.7m8, AAV5, AAV8, and AAV9, in the ARPE - 19 and HEK293 cell lines, which represent human retinal pigment epithelial cells and commonly used experimental cell lines respectively. Through fluorescence intensity assessment and flow cytometry analysis, the researchers hope to find the AAV serotype with the highest transduction efficiency, thereby providing a more effective tool for gene replacement therapy of IRDs.
### Research Background
Inherited retinal diseases (IRDs) are a group of rare, congenital, phenotypically and genotypically heterogeneous ophthalmic diseases, mainly characterized by severe visual impairment and blindness, which usually develop gradually from early to middle age. These IRDs are caused by gene mutations encoding visual light - conversion cascade enzymes in retinal photoreceptor and neuronal cells. The pathological mechanisms of IRDs involve the gradual death of photoreceptor and/or neuronal cells in the retina, leading to photophobia, decreased vision, night blindness, color vision loss, central vision loss or tunnel vision, and ultimately blindness. IRDs are the leading cause of blindness in children and working - age adults, affecting approximately 2 million people worldwide.
### Research Objectives
This study aims to determine the most efficient AAV serotype by comparing the transduction efficiencies of four serotypes, AAV2.7m8, AAV5, AAV8, and AAV9, in ARPE - 19 and HEK293 cells, in order to optimize gene replacement therapy for IRDs. The researchers used different concentrations of virus particles (1-, 3-, 6-, and 8 × 10^4 VG/cell) and evaluated the GFP expression levels by fluorescence microscopy and flow cytometry.
### Main Findings
- **AAV2.7m8 shows the highest transduction efficiency**: At all tested virus concentrations, the transduction efficiency of AAV2.7m8 in ARPE - 19 and HEK293 cells is significantly higher than that of the other three serotypes. Especially at a dose of 6 × 10^4 VG/cell, the transduction efficiency of AAV2.7m8 is 21 times that of AAV5, 202 times that of AAV8, and 323 times that of AAV9 (in ARPE - 19 cells), and 324 times that of AAV5, 100 times that of AAV8, and 52 times that of AAV9 (in HEK293 cells).
- **The difference in fluorescence intensity lasts for 4 days**: During the 4 - day observation period, the cells transduced by AAV2.7m8 always show higher fluorescence intensity, and this trend remains consistent at all virus concentrations.
- **Flow cytometry validates the results**: After 96 hours, the high - efficiency transduction ability of AAV2.7m8 was further confirmed by flow cytometry. At a dose of 6 × 10^4 VG/cell, 97% of the ARPE - 19 cells transduced by AAV2.7m8 were GFP - positive, while those of AAV5, AAV8, and AAV9 were 52%, 9%, and 9% respectively. In HEK293 cells, 95% of the cells transduced by AAV2.7m8 were GFP - positive, while those of AAV5, AAV8, and AAV9 were 12%, 17%, and 26% respectively.
### Conclusions
This study demonstrates the significant advantages of AAV2.7m8 in transducing ARPE - 19 and HEK293 cells, which provides an important reference for gene replacement therapy of IRDs. Future research can further explore the application of AAV2.7m8 in in - vivo experiments to evaluate its potential in actual treatment.